Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Receivables (2024 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 2 years of Change in Receivables data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Change in Receivables fell 27.39% year-over-year to $1.2 million; the TTM value through Sep 2025 reached -$1.5 million, changed N/A, while the annual FY2024 figure was $3.7 million, N/A changed from the prior year.
  • Change in Receivables reached $1.2 million in Q3 2025 per TNXP's latest filing, up from -$992000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.6 million in Q3 2024 and bottomed at -$1.3 million in Q4 2024.